Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 15, 2018
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - October 15, 2018

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/15/18 - +$96 Billion Opportunity for the Global Precision Medicine Market by 2023 - Featuring Abbott Labs, GE, GSK, Pfizer, J&J, Novartis, and more - ResearchAndMarkets.com
The "Global Precision Medicine Market" report has been added to ResearchAndMarkets.com' s offering. The global precision medicine market is expected to have a significant compounded annual growth rate of 9.7% and have a market size in excess of USD 96 Bn by 2023. North America dominates the global market due to the high incidence of cancer and incr
10/15/18 - 22 Stocks Moving In Monday's Pre-Market Session
Gainers Arcadia Biosciences, Inc. rose 30.3 percent to $6.49 in pre-market trading after receivings US Patent for extended shelf life wheat trait designed to increase whole grain consumption and minimize waste. XTL Biopharmaceuticals Ltd. rose 29.2 percent to $3.10 in pre-market trading. AcelRx Pharmaceuticals, Inc. shares rose 26.9 percent to $5.0
10/15/18 - 35 Stocks Moving In Monday's Mid-Day Session
Gainers XTL Biopharmaceuticals Ltd. climbed 24.6 percent to $2.99. Krystal Biotech, Inc. shares climbed 19.7 percent to $18.77 after the company's Phase 1/ 2 trial of KB103 for dystrophic epidermolysis bullosa met all primary efficacy and safety endpoints. Cambium Learning Group, Inc. climbed 19.3 percent to $14.395 after the company agreed to be a
10/15/18 - ACACIA PHARMA PROVIDES FURTHER UPDATE ON FDA REGULATORY REVIEW OF BARHEMSYS(TM)
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation No 596/ 2014. Cambridge, UK and Indianapolis, US- 15 October 2018: Acacia Pharma Group plc provides an update following receipt of a Complete Response Letter from the US Food and Drug Administration in respect of its New Drug Application for B
10/15/18 - AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Hold rating reiterated by Oppenheimer
Analyst Ratings For AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Today, Oppenheimer reiterated its Hold rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). There are 4 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is Buy with a consensus target
10/15/18 - Addiction Treatments Market Analysis on Scope & Need : This includes cost incurred to address crime, loss in work productivity, and run rehabilitation programs.
San Francisco, CA 10/15/2018 Global Addiction Treatments Market: Snapshot. The menace of drugs has been dogging our society for decades on end now. On one hand, authorities and police are trying to curtail the problem with an iron hand, on the other hand, healthcare institutes and pharmaceutical companies are pulling out all stops to cure add
10/15/18 - Advanced Drug Delivery Devices Market Projected to Garner Significant Revenues by 2025
Albany, NY 10/15/2018 Advanced drug delivery devices include drug-eluting devices that can be further categorized into biodegradable and non-biodegradable drug delivery systems. Biodegradable drug-eluting devices are used for drug delivery and after implantation these devices decompose over time. They are generally made up of biocompatible...
10/15/18 - Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada
Advicenne, a specialty pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announced today that it has received a No Objection Letter to extend its ARENA-2 pivotal Phase III trial for the treatment of distal Renal Tubular Acidosis in Canada from Health Can
10/15/18 - Aevi Genomic Medicine Announces Completion of Enrollment for Part B of the ASCEND Trial
Aevi Genomic Medicine, Inc. today announced that it has reached full enrollment of Part B of its Phase 2 ASCEND clinical trial. Part A completed enrollment in August 2018. The accelerated enrollment in Part B will allow the Company to provide complete top line data for both Parts A and B of the ASCEND trial in January 2019. Individual and pooled
10/15/18 - Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101
Aimmune Therapeutics a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron and Sanofi, of AR101 with adjunctive dupilumab in peanut-allergic patients. As quoted in the press release:. We are delighted to have Regeneron and Sanofi join u
10/15/18 - Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron and Sanofi, of AR101 with adjunctive dupilumab in peanut-allergic patients. We are delighted to have Regeneron and Sanofi join us in our commitment to imp
10/15/18 - Aimmune Therapeutics Inc (NASDAQ:AIMT) price target set to $62.00 by Cantor Fitzgerald
Analyst Ratings For Aimmune Therapeutics Inc (NASDAQ:AIMT) Today, Cantor Fitzgerald set its price target on Aimmune Therapeutics Inc (NASDAQ:AIMT) to $62.00 per share. There are 8 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Aimmune Therapeutics Inc (NASDAQ:AIMT) is Buy with a con
10/15/18 - Albireo Announces Research on Cholestatic Liver Diseases to be Presented at Major North American Liver Meetings
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that important findings from multiple studies on progressive familial intrahepatic cholestasis and other cholestatic liver diseases will be presented at major upcoming North American liver meetings.
10/15/18 - Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application
Alnylam Pharmaceuticals, the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration, the Company plans to pursue a full approval based on the complete results of the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the...
10/15/18 - Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration, the Company plans to pursue a full approval based on the complete results of the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for
10/15/18 - Alnylam Plans To Pursue Full Approval Of Givosiran, Rolling Submission Of NDA
WASHINGTON- Alnylam Pharmaceuticals Inc., an RNAi therapeutics company, said that in consultation with the U.S. Food and Drug Administration, it plans to pursue a full approval of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 or ALAS1 for the treatment of acute hepatic porphyria or AHP. Based on our positiv
10/15/18 - Anixa Biosciences Files Pre-Submission and Requests Meeting with FDA Regarding Cchek? Artificial Intelligence based Cancer Detection Technology
Anixa Biosciences, Inc., a biotechnology company focused on using the body's immune system to fight cancer, today announced it has filed an IVD pre-submission with the US Food and Drug Administration for use of its Cchek? artificial intelligence based cancer detection technology, as a prostate cancer test. Dr. Kumar continued, "This is a major
10/15/18 - AP Top Health News at 12:46 p.m. EDT
Drugmakers to disclose prices for medicines advertised on TV AP-NORC Poll: Many caregivers neglecting their own health UK offers prescription for loneliness, no drugs involved Study: Without Medicaid expansion, poor forgo medical care Marijuana legalization in Canada won't change NHL yet Guards, inmates ally against state in radon-exposure cases...
10/15/18 - Applied Therapeutics to Present New Data on Novel Investigational Treatment for Galactosemia at 2018 NORD Summit
Applied Therapeutics Inc., a privately held biotechnology company focused on developing transformative drugs in areas of high unmet medical need, announced today that it will present data on AT-007, a novel investigational aldose reductase inhibitor, at the 2018 National Organization for Rare Disorders' Rare Diseases& Orphan Products Breakthrough
10/15/18 - Arbutus Biopharma Corp (NASDAQ:ABUS) gets upgraded to Hold by Wedbush with a price target of $5.00
Analyst Ratings For Arbutus Biopharma Corp (NASDAQ:ABUS) Today, Arbutus Biopharma Corp (NASDAQ:ABUS) stock received an upgrade by Wedbush from Underperform to Hold with a price target of $5.00. There are 4 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Arbutus Biopharma Corp (NASDAQ
10/15/18 - Arbutus Biopharma Corp (NASDAQ:ABUS) gets upgraded to Neutral by Wedbush with a price target of $5.00
Analyst Ratings For Arbutus Biopharma Corp (NASDAQ:ABUS) Today, Arbutus Biopharma Corp (NASDAQ:ABUS) stock received an upgrade by Wedbush from Underperform to Neutral with a price target of $5.00. There are 4 Hold Ratings, 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock. The current consensus rating on Arbutus Biopharma Corp (NAS
10/15/18 - Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3
Arrowhead Pharmaceuticals Inc. today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 being developed for the treatment of dyslipidemias and metabolic diseases. Chris Anzalone, Ph.D., president and CEO of Arrowhead...
10/15/18 - Athenex and Xiangxue Life Sciences Announce Preliminary Results of Patients Receiving T-Cell Receptor Affinity Enhancing Specific T-Cell Therapy (TAEST) Showed Encouraging Positive Clinical Signals
Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that preliminary results of pilot studies in China in which patients received T-cell receptor affinity enhancing specific T-cell therapy showed...
10/15/18 - Auburn vet school, UAB part of joint NIH study of glioma brain cancer [Sudan Tribune]
People and animals suffering from the deadliest form of brain cancer are undergoing similar treatment in an NIH- funded clinical trial through the University of Alabama at Birmingham, Auburn Universitys College of Veterinary Medicine and two other currently enrolled Southeastern veterinary programs. Renee Chambers, who holds a doctor of veterinary.
10/15/18 - Avadel Pharmaceuticals Presents Data for NOCTIVA at 2018 American Urogynecologic Society Annual Scientific Meeting
Avadel Pharmaceuticals plc, a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, presented data from two abstracts from Phase 3 clinical trials of NOCTIVA? at the American Urogynecologic Society Annual Scientific Meeting, Pelvic Floor Disorder Week 2018 in Chicago, Illinois fro
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415